Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine

Pharmacogenetics

Volumn 13, Issue 1, 2003, Pages 19-28

  Zamber, Charis P ^a   Lamba, Jatinder K ^a   Yasuda, Kazuto ^a   Farnum, Jennifer ^a   Thummel, Kenneth ^b   Schuetz, John D ^a   Schuetz, Erin G ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ABCG2; ABCP; BCRP; MXR; Single nucleotide polymorphisms

Indexed keywords

COMPLEMENTARY DNA; GENE PRODUCT; MESSENGER RNA; PROTEIN BCRP; UNCLASSIFIED DRUG;

ALLELISM; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; INTESTINE; INTESTINE BIOPSY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL INTESTINE;

ALLELES; ATP-BINDING CASSETTE TRANSPORTERS; CELL CULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENOTYPE; HUMANS; INTESTINES; LIVER; NEOPLASM PROTEINS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER;

EID: 0037246432     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200301000-00004     Document Type: Article

References (28)

1. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95:15665-15670.
2. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999; 59:8-13.
3. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998; 58:5337-5339.
4. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse BCRP1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999; 59:4237-4241.
5. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochirn Biophys Acta 2001; 1520:234-241.
6. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, et al. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 2002; 97:626-630.
7. Rocchi E, Khodjakov A, Volk EL, Yang C-H, Litman T, Bates SE, et al. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun 2000; 271:42-46.
8. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg ACLM, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61:3458-3464.
9. Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, et al. Correlation of gene expression of 10 drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacot Exp Ther 2001; 299:164-170.
10. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RCAM, Ruevekamp-Helmers MC, et al. Overexpression of the BCRP/ MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59:4559-4563.
11. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance-half transporter (MXR), and potential glucuronidation in MXR-expressing cells. Cancer Res 1999; 59:5938-5946.
12. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999; 91:429-433.
13. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JHM, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000; 92:1651-1656.
14. Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H, et al. Identification of breast cancer resistant protein/mitoxantrone resistance/ptacenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res 2001; 61:2827-2832.
15. Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, et al. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resis-tant MCV7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 2000; 60:3514-3521.
16. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001; 280:1216-1223.
17. Litman T, Brangi M, Hudson E, Fetsch P, Abaft A, Ross DD, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Science 2000; 113:2011-2021.
18. Zhou S, Schuetz JD, Bunting KD, Colapietro A-M, Sampath J, Morris J J, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Med 2001; 7:1028-1034.
19. Honjo Y, Hrycyna CA, Yan Q-W, Medina-Perez WY, Robey RW, van de Laar A, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BORP/ABOP-overexpressing cells. Cancer Res 2001; 61:6635-6639.
20. Allen JD, Jackson SC, Schinkel AH. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res 2002; 62:2294-2299.
21. Zamboni WC, Bowman LC, Tan M, Santana VM, Houghton PJ, Meyer WH, et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacot 1999; 43:454-460.
22. Nickerson DA, Taylor SL, Weiss KM, Clark AG, Hutchinson RG, Stengard J, et al. DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene. Nature Genet 1998; 19:233-240.
23. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997; 25:2745-2751.
24. Rieder MJ, Taylor SL, Tobe VO, Nickerson DA. Automating the identification of DNA variations using quality-based fluorescence re-sequencing: analysis of the human mitochondrial genome. Nucleic Acids Res 1998; 26:967-973.
25. McLeod HL, Pritchard SC, Githang'a J, Indalo A, Ameyaw M-M, Powrie RH, et al. Ethnic differences in thiopurine methyltransferase phrmacogenetics: evidence for allele specificity in Caucasian and Kenyan subjects. Pharmacogenefics 1999; 9:773-776.
26. Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000; 98:365-368.
27. Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper PJ, Taylor CG. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematot 2001; 115:257-262.
28. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in haematopoietic stem cells. Clin Cancer Res 2002; 8:22-28.